02-05-2023 дата публикации
Номер: CN116036243A
Принадлежит:
The invention relates to the field of immunotherapy, in particular to site-specific modified PEGylated IL-2 variants, so as to provide a combination of PEGylated IL-2 variants with different receptor bias. The composition inhibits the amplification of immunosuppressive lymphocytes and reduces the terminal differentiation and depletion of effector lymphocytes through a synergistic effect, and has a synergistic anti-tumor effect, so that the composition can be used for enhancing immune response and treating proliferative diseases such as tumors. Besides, the composition can also be used for in-vitro culture of immune cells in adoptive cellular immunotherapy, aging and depletion of the immune cells are reduced, and fate of the immune cells in adoptive cellular immunotherapy is guided to long-term immunity. Thus, the invention also provides combination therapies for enhancing immune responses, treating proliferative diseases such as tumors, and in vitro methods of making or culturing immune ...
Подробнее